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Introduction: The main objectives of cardiovascular prevention are to maintain risk factor
management through lifestyle changes and use of cardioprotective medicines to reduce
morbidity and mortality, and to improve quality of life.
Objectives: To determine, in patients with coronary heart disease (CHD), whether the
treatment goals as deﬁned by the current European guidelines on secondary prevention
are implemented in clinical practice.
Methods: A total of 650 consecutive patients, men and women aged 80 years when
hospitalized for any of the following ﬁrst or recurrent discharge diagnoses or treatments
for CHD were retrospectively identiﬁed from hospital records: (i) coronary artery bypass
grafting (CABG), (ii) percutaneous transluminal coronary angioplasty (PTCA), (iii) acute
myocardial infarction (AMI), and (iv) acute myocardial ischemia. The starting date for
identiﬁcation was not less than 6 months and not more than 3 years prior to the expected
date of the study interview. Data collection was based on a review of medical records and the
interview.
Results: In total, 493 respondents were interviewed. Among them, 17% were smokers, 42%
were obese, 86% were overweight or obese, 69% had central obesity, 71% had low physical
activity, 75% had raised blood pressure (130/80 mmHg, according to the 2007 guidelines),
39% had elevated LDL-cholesterol (2.5 mmol/l), and 48% had overt diabetes (declared
diabetes treatment or fasting glucose >7.0 mmol/l). At interview, 92% of patients were
treated with aspirin or other antiplatelets, 85% with beta-blockers, 82% with ACE inhibitors
or angiotensin receptor blockers (ARBs), and 93% with statins. Only a minority of the patients
followed the non-pharmacologic secondary prevention recommendations.
Conclusion: Among coronary patients, prevalence of overweight, obesity, and diabetes in-
creased. Although pharmacotherapy is used in a majority of secondary prevention in
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patients, the recommended levels of blood pressure, lipid, and glucose metabolism are
largely not achieved. Also, implementation of non-pharmacologic interventions of lifestyle
factors remains unsatisfactory.
# 2014 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp. z o.o.
All rights reserved.
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.Introduction
Cardiovascular disease continues to be the leading cause of
death in Czech Republic and Europe alike. Preventive lifestyle
modiﬁcations (i.e., smoking, diet, and physical activity)
together with effective control of hypertension, hyperlipid-
emia, and diabetes as well as preventive pharmacotherapy
[use of antiplatelet agents, beta-blockers, ACE inhibitors and
angiotensin receptor blockers (ARBs) or statins], combined
with other therapeutic procedures, delay the ﬁrst presentation
of coronary heart disease (CHD) as well as recurrent coronary
events thus signiﬁcantly reducing CHD morbidity and mortal-
ity rates.
Preventive management of patients with overt CHD was
deﬁned in detail by the European guidelines on cardiovascular
disease prevention in clinical practice. The guidelines were
ﬁrst published in 1994 while their revised version, developed
already jointly with several other European societies, appeared
in 1998; the 2003 guidelines extended prevention to all
manifestations of atherosclerotic vascular disease. The fourth
edition of the guidelines in 2007 incorporated, among other
things, estimation of the risk of death from cardiovascular
disease using SCORE charts [1]. The most recent (ﬁfth)
guidelines, published in 2012, in addition to extending the
list of risk factors, risk markers, and methods of their
estimation, further include new and speciﬁc strategies in
cardiovascular prevention [2]. Several Czech-language guide-
lines on the same issue have also been developed.
In order to assess ‘‘real-life’’ secondary prevention of CHD,
implementation of and adherence to the guidelines, four
cross-sectional EUROASPIRE (European Action on Secondary
and Primary Prevention by Intervention to Reduce Events)
surveys were performed: the ﬁrst in 1995–1996, followed by
one in 1999–2000, another in 2006–2007 and, ﬁnally, EURO-
ASPIRE IV covering the 2012–2013 period (EUROASPIRE I-IV). Of
the original nine countries involved in the survey, the number
of participating countries has grown to 24. The Czech Republic,
with its two centers (Plzeň and Prague), has participated in all
four surveys; results of the ﬁrst three surveys were published
showing both European and, separately, Czech data [3–7]. A
speciﬁc feature of the EUROASPIRE IV study is that it allows its
investigators to compare their data both with the 2007 and
2012 guidelines.
The aim of the present paper is to report on results of the
latest survey conducted in two Czech centers from July 2012
through April 2013. The current status of risk factor control,
intervention of lifestyle factors, and use of cardioprotective
medications was compared primarily with the fourth and,
also, ﬁfth guidelines. Special attention was given to patients
with diabetes. The authors of the present study suggest that itwill take some more time to get the most of the potential of
secondary prevention in patients who manifest CHD in the
Czech Republic.
Method
Survey design and patients
In the Czech Republic, this cross-sectional survey of secondary
prevention in patients with clinically manifested CHD was
conducted within the EUROASPIRE study in two centers,
namely the Prague-based Institute for Clinical and Experi-
mental Medicine (IKEM) and the University Hospital in Plzeň
(Pilsen). Both centers participating in the previous surveys
were selected to provide all types of care to cardiac patients
while catering to catchment areas with a population of at least
half a million.
We identiﬁed, both restrospectively and consecutively,
patients (men and women) aged 80 years at the time of
hospitalization for at least one of the following diagnoses: (1)
elective or emergency coronary artery bypass surgery (CABG);
(2) elective or emergency percutaneous coronary angioplasty;
(3) acute myocardial infarction (STEMI or non-STEMI); and (4)
acute myocardial ischemia. Eligible for inclusion were patients
(ﬁrst or a repeat) hospitalized not less than 6 months and not
more than 3 years prior to the expected date of the study
interview. Overall, 650 patients were selected. The interviews
were held from July 2012 to April 2013.
Study protocol
The survey was performed in compliance with the standard
EUROASPIRE IV study protocol. During the interview, each
respondent's history was taken including their personal and
demographic characteristics, personal and family history of
cardiovascular disease, data on adherence to principles of a
healthy lifestyle, and pharmacotherapy. Standardized mea-
surements were made as per protocol using calibrated devices,
with blood sampling and patients completing the following
questionnaires:
a) Body weight in light-fabric attire without footwear (SECA
701 scales, SECA GmbH, Hamburg, Germany) with an
accuracy of 0.1 kg, and body height using a stadiometer
(SECA model 220) with an accuracy of 0.5 cm. Waist
circumference was measured using a steel measuring tape
at mid-distance between the spina ilica anterior and the
lower edge of the ribcage.
b) Blood pressure (BP) was measured by a physician twice after
at least a 10-min rest in the sitting position on the right arm
Table 1 – Basic characteristics of the group of respondents
and risk factor profile at the time of interview.
N 493
Age [yrs] 65.9 (9.02)
Sex [% of females] 19.7
Body mass index [kg/m2] 29.5 (4.26)
Waist circumference [cm] 104.6 (11.6)
Systolic blood pressure [mmHg] 136.4 (18.8)
Diastolic blood pressure [mmHg] 82.0 (10.7)
Heart rate [b.p.m.] 68.3 (10.4)
Total cholesterol [mmol/l] 4.36 (1.00)
HDL-cholesterol [mmol/l] 1.17 (0.27)
LDL-cholesterol [mmol/l] 2.37 (0.80)
Triglycerides [mmol/l] 1.81 (1.05)
Fasting glycemia [mmol/l] 6.98 (2.09)
The values are mean (SD) unless stated otherwise.
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(Omron, Healthcare Ltd., Milton Keynes, UK). In cases where
the difference between the ﬁrst and second measurements
was greater than 10 mmHg, BP was measured twice again,
with the ﬁnal value being the mean of the ﬁrst or the last
two measurements.
c) Carbon monoxide levels in expired air was measured in
ppm using a smokelyser device (Micro + Bedfont Scientiﬁc,
Upchurch, United Kingdom). Smoking at the time of
interview was deﬁned as smoking self-reported by the
patient and/or breath CO levels >10 ppm [8]. Continued
smoking after the index event was deﬁned as the number of
current smokers related to the number of smokers at the
time of the index event.
d) Blood samples were obtained by venipuncture after at least
12-h fasting. The serum separated from venous blood
samples was analyzed in local laboratories (IKEM a Pilsen
University Hospital) and stored at 70 8C to be subsequently
shipped (frozen) to the central laboratory at the Disease
Risk Unit, National Institute for Health and Welfare, Helsinki,
Finland. Results from the Helsinki-based central laboratory
performing all analyses using a clinical chemical analyzer
(Architect c8000, Abbott Laboratories, Abbott Park, IL, USA),
are shown below. Total cholesterol (TC) was determined
enzymatically, HDL-cholesterol (HDL) and triglycerides (TG)
were analyzed using kits manufactured by Abbott Laborato-
ries (USA), and LDL-cholesterol (LDL) levels were calculated
using a modiﬁed Friedewald method (i.e., TC-HDL-TG/2.2) [9].
Venous blood glucose was determined by a photometric
point-of-care technique (Glucose 201, HemocueR, Ängel-
holm, Sweden, with a coefﬁcient of variation of 2.8%). Our
deﬁnition of diabetes was self-reported diabetes at interview
based on a history of diabetes diagnosed by a physician. In
those without a history of diabetes, fasting plasma glucose
levels 7.0 mmol/L was deﬁned as new-onset diabetes. The
Helsinki-based laboratory participates in the Lipid Standard-
ization Program run by CDC, Atlanta, USA, and the Program
of External Quality Assessment run by Labquality, Helsinki,
Finland.
e) The outpatient examination in non-diabetic respondents
included the oral glucose tolerance test. Venous blood
glucose was determined by photometry (Glucose 201,
HemocueR, Ängelholm, Sweden). Diabetic patients were
deﬁned as those reporting diabetes diagnosed previously by
a physician whereas new-onset diabetes was deﬁned as
fasting glucose levels 7.0 mmol/l not previously in
detected in their personal history.
f) Additionally, the following standardized tools were com-
pleted for each patient: IPAQ (International Physical Activity
Questionnaire) to quantify the level of physical activity, SF 12
(Short Form 12 health survey) to objectify quality of life, and
HADS (Hospital Anxiety Depression Scale) to objectify
depression or anxiety. All these three tools have been
validated internationally [10–12], and their validated Czech-
language versions were used for the purpose of our study.
Data collection and processing, statistical methods
Data excerpted from the medical records of the patients and
those obtained during interview were entered into Case Report
Forms (CRFs); the forms are available in the Czech centers,both in printed and electronic format. Electronic CRFs were
forwarded to the data processing center (Euro Heart Survey
department, European Heart House, Nice, France) and checked
for completeness, consistency, and accuracy to be subse-
quently processed. For the purpose of this interim report on
the course and results of the study, the data were processed
only using descriptive statistics. Our limits for categorization
of continuously monitored risk factors were identical to the
target values of secondary prevention as per the respective
guidelines [1,2].
Ethical issues
The study was performed in conformity with the principles of
Good Clinical Practice; the study protocol was approved by the
respective local ethics committees, and all participants signed
their informed consent forms. Data were stored in accordance
with the applicable regulations.
Results
After reviewing hospitalization medical records, a total of 650
patients were invited to the interview. The interview was
attended by, and the required data were obtained from 493
respondents; thus, the response rate was 75.9%. Mean time
between the index event (i.e., acute coronary event and/or
revascularization) and the interview was 1.33 years. Basic
demographic data and the mean numbers of major risk factors
in our group are shown in Table 1. Mean age at the time of
interview was 65.9 years (SD 9.02); the group consisted mostly
of men (80.3%). We found markedly increased mean values of
BMI, waist circumference, and fasting glycemia. Based on their
diagnosis of cardiovascular disease, 94% of the patients
reported being on regular follow-up by a cardiologist, 3% by
an internist or a general practitioners each, while 26% of the
patients were also being treated by a diabetes specialist.
Table 2 gives the percentages of respondents failing to meet
the goal values of clinical and laboratory parameters deﬁned
by the 2007 and 2012 guidelines for secondary prevention.
An increased body mass index (BMI 25 kg/m2) was found
in 85.6% of the patients, with 41.8% of these already being
Table 2 – Basic risk factors categorized by 2007 and 2012
guidelines [%].a,b
Body measures
Overweight or obesity (BMI25 kg/m2) 85.6
Obesity (BMI 30 kg/m2) 41.8
Increased waist circumferencea 68.9
Smoking
Current smokers 17.4
Continued smoking after index eventb 48.6m
Hypertension
Blood pressure 130/80 mmHg 75.0
Blood pressure 140/90 or 140/80 in diabetics 49.1
Blood pressure 180/100 mmHg 6.2
Inadequate blood pressure control, 2007 guidlinesc 81.1m
Inadequate blood pressure control, 2012 guidelinesd 54.8m
Lipids
Total cholesterol 4.5 mmol/l 40.2
LDL-cholesterol 2.5 mmol/l 38.7
LDL-cholesterol 1.8 mmol/l 76.5
Inadequate control of hypercholesterolemia,
2007 guidelinese
47.7m
Inadequate control of hypercholesterolemia,
2012 guidelinesf
77m
Triglyceridyes1.7 mmol/l 40.1
Low HDLg 33.5
Glucose metabolism
Overt diabetesh 47.8
Inadequate control of diabetesi 90.2m
Inadequate control of diabetesj 61.8m
Impaired glucose tolerancek 17.5
Impaired fasting glycemial 9.3
a Waist circumference 102 cm in males or 88 cm in females.
b proportion of current smokers related to the number of smokers
at the time of the index event.
c BP 130/80 mmHg, related to the number of patients treated with
antihypertensives.
d BP 140/90 mmHg or 140/80 mmHg in diabetics, related to the
number of patients treated with antihypertensives.
e total cholesterol 4.5 mmol/l or LDL cholesterol 2.5 mmol/l,
related to the number of patients treated with lipid-lowering
agents.
f LDL cholesterol 1.8 mmol/l, related to the number of patients
treated with lipid-lowering agents.
g <1.0 mmol/l in males or <1.2 mmol/l in females.
h Previously diagnosed diabetes or fasting glycemia 7 mmol/l.
i Fasting glycemia 6.1 mmol/l, related to the number of patients
with overt diabetes.
j HbA1c 6.5%, related to the number of patients with overt
diabetes.
k Post-exercise glycemia 7.8–11 mmol/l, but absence of overt
diabetes (see above).
l Fasting glycemia 6.1 mmol/l, but absence of overt diabetes or
impaired glucose tolerance.
m Not related to total number of respondents.
Table 3 – Cardiovascular pharmacotherapy used at the
time of interview [%].
Antiplatelets or anticoagulants 92.7
Acetylsalicylic acid 86.6
Dual antiplatelet therapy 38.5
Anticoagulants 8.9
All antihypertensives 94.5
Beta-blockers 85.4
ACE inhibitors or angiotensin receptor blockers 81.9
All diuretics 41.0
Furosemide and/or spironolactone 23.7
All lipid-lowering agents 93.7
Statins 92.9
Fibrates 3.45
Ezetimibe 2.0
All antidiabetic agents 29.0
Oral antidiabetics 24.5
Insulin 8.3
Anti-anginal agents 14.4
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circumference 102 cm in males and 88 cm in females) was
documented in 68.9% of the respondents. Prevalence of
smoking at the time of interview was 17.4%; of the original
smokers, 48.6% continued to smoke after the event. A blood
pressure (BP) level in excess of the value recommended in the
2007 guidelines (BP <130/80 mmHg) was present in 75% of the
patients, BP levels higher than those recommended by the2012 guidelines (BP <140/90 or <140/80 mmHg in patients with
diabetes) were found in 49.1% of the group. Among patients on
antihypertensive therapy, only 18.9% achieved the BP levels
recommended in the 2007 guidelines; the ﬁgure rose to 45.2% if
the levels set by the 2012 guidelines are considering. Regarding
lipid metabolism parameters, target LDL (LDL <2.5 mmol/l)
levels as per the 2007 guidelines were achieved by 61.3% of the
patients; when applying the more stringent values (LDL
<1.8 mmol/l) deﬁned by the 2012 guidelines, the ﬁgure was
23.5%. Among the patients treated with lipid-lowering drugs,
52.3% of the patients met the target values recommended in
2007, but only 23% when applying the levels recommended in
2012. Hypertriglyceridemia was diagnosed in 40.1%, and low
HDL levels in 33.5% of the patients. The prevalence of
previously diagnosed and new-onset diabetes was 47.8%, with
another 17.5% of the patients found to have impaired glucose
tolerance; 9.3%. of the respondents had increased fasting
glucose. Only 9.8% of the patients had fasting glucose levels
<6.1 mmol/l.
Table 3 shows the percentage of patients on pharmaco-
therapy recommended in secondary prevention to control
individual risk factors or for symptomatic therapy. Antiplate-
let or anticoagulation therapy was used by 92.7% of the
patients while 38.5% of the respondents were on dual
antiplatelet therapy. Medications used as antihypertensives
and, also, as cardioprotective agents were prescribed to 94.5%
of the patients. In terms of the drug classes used, beta-blockers
were taken by 85.4%, ACE inhibitors and angiotensin receptor
blockers (ARBs) by 81.9%, with diuretics used by 41% of the
patients; lipid-lowering agents by 93.7%, statins by 92.9%, and
ﬁbrates by 34.5% of the patients. Altogether, oral antidiabetic
and/or insulin were used by 29% of the patients (oral
antidiabetics, 24.9%; insulin, 8.3%).
Table 4 shows adherence to a healthy lifestyle. The level of
usual daily physical activities was determined using the IPAQ
tool. None or low physical activity was reported by 71%, mild to
moderate by 7%, and high physical activity (mainly driven by
reported walking) by 22% of the patients. Regular, intentional
physical activity was reported by 25.1% of the respondents.
Fifty-eight to 67.5% of the patients said they adhered to dietary
Table 4 – Self-reported non-pharmacological secondary
preventive measures and lifestyle changes initiated after
the index event [%].
Physical activity
Classiﬁcation of daily physical activitya:
Low 71.0
Medium 7.0
High 22.0
Regular, intentional physical activityb 25.1
Measures adopted to increase physical activity:
- as recommended by the rehab professional 10.8
- visits a ﬁtness center 5.5
- has increased routine daily physical activity 24.1
Diet
Low-fat diet 67.5
Change in fat composition 60.0
Reduced salt intake 60.0
Low sugar diet 58.0
Reduced caloric intake 58.0
Measures adopted to break smoking habitc
Quit smoking 8.1
Reduced smoking frequency 65.1
Nicotine replacement therapy 8.1
Visited a smoking cessation center 2.3
Used varenicline or bupropione 2.3
Measures adopted to reduce body weightd
Adheres to speciﬁc dietary recommendations 58.3
Has regular physical activity 46.1
Used antiobesity agents 3.9
a According to IPAQ (see ‘‘Methods’’ section).
b Physical activity such as jogging, cycling, aerobics, etc., per-
formed regularly at least 2–5 per week, each time for at least 3é
minutes.
c Related only to the number of current smokers at the time of
interview.
d Related only to the number of obese patients at the time of
interview.
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the most frequent dietary measure being a reduced fat intake.
Among obese patients, 58.3% stated they adhered to dietary
recommendations and 46.1% claimed to practice regular
physical activity. Only a small fraction of those smoking after
the index event sought advice from a smoking cessation center
or started to use replacement therapy.
The presence of psychosomatic depression and anxiety
was assessed using the standard HADS tool (see Table 5).
Possible or probable depressive disorder (HADS Score 8) wasTable 5 – Psychosocial factorsa and their managements at
the time of interview [%].
Possible or probable depression 23.7
Possible or probable anxiety 17.4
Antidepressants 2.6
Anxiolytics 1.8
a According to HADS (see ‘‘Methods’’ section), categorized as a
HADS score within the respective dimension 8. Internal Grant
Agency of Ministry of Health, Czech Republic (grant No. 13186). All
study participants agreed voluntary to participate in the research
project and signed the Informed Consent Form approved by Ethical
Committee.diagnosed in 23.7% of the patients, and increased anxiety in
17.4% of the patients. Antidepressants and anxiolytics were
used only rarely.
Discussion
The EUROASPIRE IV study is a cross-sectional descriptive one
conducted in 2012–2013 and designed to assess the state of
CHD secondary prevention in clinical practice and to docu-
ment the rates for achieving therapeutic goals, as deﬁned by
the 2007 and 2012 guidelines, by patients with overt CHD [1,2].
Perhaps the critical and most important step for smokers in
CHD secondary prevention is smoking cessation. In our group,
two thirds of smokers quit smoking, and the prevalence of
smoking (17.4%) among our respondents is lower compared
with the general Czech population (according to Czech post-
MONICA study data from 2006 to 2009, there are 34% male, and
26.9% female smokers [13]; still, the ﬁgure is slightly higher
than the European average [16%]). Those of our patients who
quit smoking did so more or less spontaneously, aware as they
were about the harmfulness of smoking, occasionally also for
ﬁnancial reasons. A major role is played by their experience
with the event and revascularization procedure; however,
with improving coronary event prognosis, shortening length of
hospitalization, and increasing proportion of revasculariza-
tion procedure being catheter-based, the motivation of
patients to quit smoking may be decreasing.
The patients who continue smoking after the event do so
not because of lack of information, but because of their heavy
addiction comparable with dependence on heroin. Half of
these patients claim they would very much like to break the
habit. However, the effect of a mere recommendation – no
matter how often repeated by the physician – is very limited
unless followed by other measures. A time-proven strategy is a
comprehensive approach practiced by smoking cessation
centers. The success rate of nicotine rehab/addiction therapy
is boosted by supportive pharmacotherapy: nicotine replace-
ment therapy, use of bupropione or varenicline. However,
these therapeutic options were used only minimally in our
group. Failure to quit smoking in patients with manifest CHD
cannot be tolerated; in addition to substantially more restric-
tive legislation regulating smoking and more aggressive
treatment of addiction, measures should be considered in
the health care insurance system such as co-payment by
smokers for their future therapy.
Another major risk factor in secondary prevention of CHD is
arterial hypertension or, more precisely, its inadequate
control. The 2007 and 2012 guidelines differ substantially on
this issue; the latter guidelines discarded the rather contro-
versial trend of reducing BP levels to the lowest possible values
to recommend, instead of BP levels <130/80 mmHg for all the
patients with established CHD, new BP levels <140/90, and
<140/80 mmHg for those with diabetes.
The 2007 guidelines clearly failed to gain widespread
acceptance (with only 25% of the patients having the
recommended BP levels); however, even the revised BP levels
were only achieved by half of our patients, i.e., essentially the
ﬁgure seen in the general population [14]. Some antihyper-
tensives were used by the overwhelming majority of the
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tory and poorer than the European average of the study, where
the recommended values of those treated by antihyperten-
sives were achieved by 29% and 53%, respectively. This may be
due to both poor patient compliance and the fact that
prescription is generally focused on cardioprotection rather
than on targeted BP control. The doses and combinations
prescribed are inadequate to achieve the recommended BP
levels.
Blood pressure levels were not measured until during the
interview, after at least a 10-min rest in the sitting position.
The Omron device seemed to be reliable, the values were
consistent, without major ﬂuctuations. However, the mean of
the ﬁrst two measurements used in the vast majority of the
patients may overestimate BP levels vs. the strategy consider-
ing the mean of the second and the third measurements. In the
Czech post-MONICA study, the latter approach, as compared
with the former, tended to decrease the prevalence of
hypertension in the population from 43.6% to 40% while
improving hypertension control from 24% to 31% [15]. Given
this methodological problem, the true prevalence of poor BP
control in this study is apparently lower than reported here.
Compared with data from previous EUROASPIRE studies,
the mean levels of atherogenic lipid values in our group further
declined consistently with the trend seen in the general
population [6,7,13]. Here again, as with antihypertensive
drugs, most of the patients were treated with lipid-lowering
drugs and, compared with the previous EUROASPIRE study, the
proportion of treated patients further increased (from 84% to
93.7%). Within this class of drugs, the dominant position is
again taken by statins, while ezetimibe (almost exclusively in
combination with a statin) and ﬁbrates were used only
occasionally in our group.
The introduction of more stringent recommended values
resulted in a clearly opposite shift compared with BP control.
While, using the 2007 criteria, the recommended levels of
lipids were found in 60% of the group (Table 2), when applying
the stricter criteria published in 2012 (LDL cholesterol
<1.8 mmol/l), the recommended levels were achieved by only
23.5% of our patients, and 23% of the respondents on lipid-
lowering therapy. The secular trend of a decrease in the levels
of atherogenic lipids and expansion of lipid-lowering therapy
thus lags behind the trend toward decreasing the target goal
values of lipidemic parameters. While the attending physi-
cians, mostly cardiologists, did adopt the recommendation to
give statins in secondary prevention, they mainly prescribe –
as with antihypertensive drugs – insufﬁciently effective doses.
A most alarming ﬁnding in our group is the high prevalence
of diabetes. Virtually half of all the patients currently have
diabetes. In the European context, the prevalence of diabetes
among Czech coronary patients is the third highest after
Cyprus and Greece. Only one in four of our patients have
normal glucose metabolism. Diabetes control, particularly
short-term (assessed by fasting glycemia) but, also, long-term
diabetes control (assessed by glycated hemoglobin) was
simply inadequate; this contrasts with the fact that more
than half of the patients with diabetes were treated by diabetes
specialists. However, the most recent guidelines substantially
lower the limit values of fasting glycemia and glycated
hemoglobin in coronary patients. The continuing trend towardincreasing diabetes prevalence is a global one and apparently
closely related to the rising prevalence of obesity.
The prevalence of overweight, obesity, and particularly
abdominal obesity, further rose making the Czech Republic
rank among countries with the highest prevalence. It is
primarily abdominal obesity that is largely disregarded; only
18% of our patients had their waist circumference measured
after the index event while the ﬁgure was 30% elsewhere in
Europe.
Non-pharmacological strategies in secondary prevention of
CHD were addressed in the protocol in much detail and in
alternative versions. Still, self-reported data by patients on
their adherence to the above strategies should be regarded as
appreciably overestimated. Forty-ﬁve percent of the patients
reported physical activity (mainly walking) classiﬁed as high,
whereas 28% of the patients admitted no or very little physical
activity. However, regular intentional physical activity was
only reported by one in four patients and only few of our
patients were involved in long-term cardiovascular exercise
and rehabilitation programs. In the Czech Republic, long-term
cardiovascular exercise and rehabilitation programs are
available in only few centers and currently not yet supported
by health care insurance policies; at the same time, it is one of
the most effective strategies in secondary prevention of CHD
[16].
The vast majority of the patients are aware of recom-
mended dietary measures and 58–68% of them claim reduced
caloric intake, restricted sugar intake, reduced dietary salt
intake, reduced fat consumption, and change in the composi-
tion of dietary fats. While laboratory ﬁndings suggest a long-
term tendency toward decreased cholesterol levels, the dietary
measures self-reported by patients clearly fail to help reduce
their body weight.
A comprehensive program of treatment and prevention is
available/offered almost exclusively as spa treatment follow-
ing immediately after a revascularization procedure (CABG). A
hospital stay, usually no longer than a few days, for AMI
patients managed by direct PTCA or conservatively, or even
shorter hospitalization for elective PTCA initiates or modiﬁes
pharmacological strategies of secondary prevention of CHD
and provide patients with basic information about non-
pharmacological preventive measures; however, they usually
are not followed by medium- and long-term comprehensive
programs of cardiovascular prevention (diet, physiotherapy,
and other). Nonetheless, 49% of the patients reported they had
been offered a program of cardiovascular prevention and
rehabilitation, with 38% of these in fact stating they had
participated in such a program (including patients indicated
for spa-based rehabilitation); this ﬁgure is consistent with the
European average. The overwhelming majority of patients
(94%) said they continued to be followed up by a cardiologist.
There is no doubt that there is still much room for
improvement both in the aggressiveness of pharmacotherapy
and in the comprehensive approach of non-pharmacological
secondary prevention.
Major risk factors adversely affecting quality of life as well
as the prognosis of CHD patients are generally believed to
include depression and anxiety [17]. This notion was sup-
ported in our group with possible or probable depressive or
anxiety disorders experienced in a major proportion of
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 1 0 5 – e 1 1 2 e111patients (23.7% and 17.3%, respectively). Although adequate
therapy has been shown to improve quality of life, only one in
ten patients developing these disorders were in fact appropri-
ately treated with antidepressants or anxiolytics.
The study is fraught with several limitations. First, it
documents the status quo in only two Czech regions
[catchment areas of Pilsen University Hospital and IKEM
(Prague 4)]. Second, the respondents were patients treated
primarily in two centers offering highly specialized care (as per
the study protocol) and apparently providing also above-the-
standard management to cardiac outpatients (94% patients on
follow-up by a cardiologist after the index event). This makes
patient selection largely selective and one can only speculate
to what extent the ﬁgures are truly representative for the
whole country. However, judging by data from other studies
and registries, the inter-regional differences are gradually
becoming smaller [18]. Some caution is to be exercised when
reviewing self-reported data on physical activity, diet, and
other lifestyle factors as some degree of overestimation should
be suspected.
A major advantage is the possibility, afforded by the
standardized EUROASPIRE protocol, to compare data both over
time in the EUROASPIRE I–IV studies, and with other individual
European centers as well as with aggregate European data at a
given point of time.
In summary, the standard of comprehensive secondary
prevention in patients with overt CDH, provided mostly high-
quality and costly care in the acute stage of their disease,
continues to be unsatisfactory. This is in stark contrast with
the results of the Czech IMPACT study, where the reduction of
mortality from CDH obtained by secondary prevention after an
AMI was greater compared with the reduction of mortality
obtained by acute management of patients experiencing an
AMI [19]. Continued pharmacological secondary prevention
fails to achieve target values, particularly because of inade-
quately low doses prescribed. Likewise, patients are not
sufﬁciently encouraged to change and adopt a healthy lifestyle
as well as join training programs of cardiovascular rehabilita-
tion, healthy diet, and smoking cessation. Lamentably, there is
also still much room for improvement in terms of orchestrat-
ing efforts with counseling and support centers without
leaving the brunt of care on the cardiologist. The same applies
to activities of a variety of support and non-proﬁt organiza-
tions and alliances such as the European Heart Network. All in
all, while acute management of patients with CHD (AMI) is
virtually at its best, the role currently played by the less
expensive and potentially most rewarding secondary care is
still inadequate.
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